JP2011529912A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529912A5
JP2011529912A5 JP2011521353A JP2011521353A JP2011529912A5 JP 2011529912 A5 JP2011529912 A5 JP 2011529912A5 JP 2011521353 A JP2011521353 A JP 2011521353A JP 2011521353 A JP2011521353 A JP 2011521353A JP 2011529912 A5 JP2011529912 A5 JP 2011529912A5
Authority
JP
Japan
Prior art keywords
peg
lipid
cholesterol
nanoparticle
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011521353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529912A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/052396 external-priority patent/WO2010014895A2/en
Publication of JP2011529912A publication Critical patent/JP2011529912A/ja
Publication of JP2011529912A5 publication Critical patent/JP2011529912A5/ja
Pending legal-status Critical Current

Links

JP2011521353A 2008-07-31 2009-07-31 核酸送達システム用のナノ粒子組成物 Pending JP2011529912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8528908P 2008-07-31 2008-07-31
US61/085,289 2008-07-31
PCT/US2009/052396 WO2010014895A2 (en) 2008-07-31 2009-07-31 Nanoparticle compositions for nucleic acids delivery system

Publications (2)

Publication Number Publication Date
JP2011529912A JP2011529912A (ja) 2011-12-15
JP2011529912A5 true JP2011529912A5 (enExample) 2012-07-26

Family

ID=41610973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521353A Pending JP2011529912A (ja) 2008-07-31 2009-07-31 核酸送達システム用のナノ粒子組成物

Country Status (6)

Country Link
US (1) US20110111044A1 (enExample)
EP (1) EP2304026A4 (enExample)
JP (1) JP2011529912A (enExample)
CA (1) CA2731173A1 (enExample)
TW (1) TW201004658A (enExample)
WO (1) WO2010014895A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101838308B1 (ko) * 2010-02-22 2018-03-13 큐알엔에이, 인크. 피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료
JP2013524811A (ja) * 2010-04-20 2013-06-20 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド ナノザイム、ナノザイムの製造方法、およびナノザイムの使用方法
WO2012058483A1 (en) 2010-10-28 2012-05-03 Pacira Pharmaceuticals, Inc. A sustained release formulation of a non-steroidal anti-inflammatory drug
US8709466B2 (en) 2011-03-31 2014-04-29 International Business Machines Corporation Cationic polymers for antimicrobial applications and delivery of bioactive materials
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014070069A1 (en) * 2012-11-02 2014-05-08 Telefonaktiebolaget L M Ericsson (Publ) Network node, user node and methods for channel estimation
WO2014106856A1 (en) * 2013-01-03 2014-07-10 Council Of Scientific & Industrial Research Mannose-receptor selective lysinylated cationic amphiphiles and a process for preparation thereof
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
DK3019619T3 (da) 2013-07-11 2021-10-11 Modernatx Inc Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
HK1209324A1 (en) 2013-08-14 2016-04-01 佛罗里达大学研究基金会公司 Nanozymes, methods of making nanozymes, and methods of using nanozymes
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
PL3350333T3 (pl) 2015-09-17 2022-03-07 Modernatx, Inc. Polinukleotydy zawierające region stabilizujący ogon
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
CN112587504B (zh) * 2016-10-17 2022-10-18 南京绿叶制药有限公司 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
CA3071968A1 (en) 2017-08-04 2019-02-07 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticle
CN120204165A (zh) * 2018-01-18 2025-06-27 伊泽阿恩埃免疫疗法股份有限公司 脂质纳米颗粒
JP7555123B2 (ja) 2018-10-09 2024-09-24 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア 有機溶媒不含かつ劣化剤不含のトランスフェクション・コンピテント・ベシクルを含む組成物及びシステム並びにそれらに関連する方法
CN109549934B (zh) * 2018-12-25 2021-03-09 上海交通大学 一种多糖基脂质纳米粒子的制备方法
WO2022251959A1 (en) * 2021-06-01 2022-12-08 Nanovation Therapeutics Inc. Dna vector delivery using lipid nanoparticles
EP4248949B1 (en) 2022-03-21 2024-08-28 R.G.C.C. Holdings AG Liposomal compositions
US11951177B2 (en) 2022-03-23 2024-04-09 Nanovation Therapeutics Inc. High sterol-containing lipid nanoparticles
US12011507B2 (en) 2022-04-01 2024-06-18 Nanovation Therapeutics Inc. MRNA delivery composition
WO2024085149A1 (ja) * 2022-10-18 2024-04-25 第一三共株式会社 テイラー反応装置及びカプセル粒子の製造方法
WO2025021083A1 (en) * 2023-07-24 2025-01-30 National Institute Of Biological Sciences, Beijing Lipid nanoparticle compositions for localized treatment of skin diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US20010007771A1 (en) * 1996-05-29 2001-07-12 Sean M. Sullivan Cationic polymers and lipids for the delivery of nucleic acids
WO1998051278A2 (en) * 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6841537B1 (en) * 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US7514099B2 (en) * 2005-02-14 2009-04-07 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20080207542A1 (en) * 2002-03-26 2008-08-28 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20060051405A1 (en) * 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2638807A1 (en) * 2006-02-01 2007-08-09 The Burnham Institute For Medical Research Lymphatic zip codes in tumors and pre-malignant lesions
US20070293449A1 (en) * 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
AU2007296055A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties

Similar Documents

Publication Publication Date Title
JP2011529912A5 (enExample)
JP2011520983A5 (enExample)
JP5795072B2 (ja) Rna干渉を誘導する核酸分子及びその用途
JP2012509258A5 (enExample)
CA2859127C (en) Novel oligonucleotide conjugates and use thereof
US9006191B2 (en) Silencing of polo-like kinase expression using interfering RNA
KR101752812B1 (ko) 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법
JP2012509272A5 (enExample)
JP2012509366A5 (enExample)
JP2012509273A5 (enExample)
ES2809481T3 (es) Estructura de oligonucleótidos de tipo nanopartícula mejorada que tiene alta eficiencia y método para preparar la misma
JP2015518373A5 (enExample)
JP2014530602A (ja) アルデヒドデヒドロゲナーゼをサイレンシングするための組成物および方法
JP2015502365A5 (enExample)
JP2011509258A5 (enExample)
WO2015082080A1 (en) Means for lung specific delivery
Bhavsar et al. Translational siRNA therapeutics using liposomal carriers: prospects & challenges
JP2023539341A (ja) Dux4阻害剤およびその使用方法
KR102701681B1 (ko) 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물
CN120077134A (zh) 靶向apoc3的多核酸分子及其用途
CN107630015B (zh) 一种稳定的dna-rna双链结构
WO2023168202A2 (en) Certain dux4 inhibitors and methods of use thereof
JP2025540278A (ja) 修飾免疫調節薬
Zhang Anti-miRNA Delivery Systems Based on Self-assembled Nanostructure
AU2013202970A1 (en) Silencing of polo-like kinase expression using interfering RNA